Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18720621 | 0.83 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL2487056 | 0.77 | CYP2C19 (0.41) | ALDH1A1 | |
| SCHEMBL12360854 | 0.77 | ALDH1A1 (0.38) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL18503506 | 0.76 | — | — | |
| SCHEMBL17613653 | 0.75 | CA12 (0.30) | CA12CA1CA2CA9 | |
| SCHEMBL13190642 | 0.75 | CA12 (0.32) | CA12CA1CA2CA9 | |
| SCHEMBL26636024 | 0.75 | CCNE2 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL13656413 | 0.74 | CA12 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL17613650 | 0.73 | CA12 (0.34) | CA12CA1CA2CA9 | |
| SCHEMBL19632880 | 0.73 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | TYMP, NSUN2, PNP | ALDH1A1 1181/4885CA12 2536/4885CA1 2449/4885 |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | NUDT1, NTPCR, ENTPD5 | ALDH1A1 1553/4885CA12 4226/4885CA1 4761/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ALDH1A1 4183/4885CA12 4732/4885CA1 4630/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ALDH1A1 4105/4885CA12 4733/4885CA1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.